Biology › Practise › Questions › Genome analysis, genetic screening and gene therapy
Questions on genome analysis, genetic screening and gene therapy
DNA sequencing and what a genome project produces; DNA probes and microarrays; genetic screening and the role of genetic counselling; DNA profiling using variable number tandem repeats and how a match probability should be interpreted; and somatic against germ line gene therapy with the arguments on each side.
15 original questions · 53 marks · the genome analysis, genetic screening and gene therapy notes · Gene regulation, genomics and biotechnology
To print: the written questions (PDF, 53 KB) · the mark schemes (PDF, 65 KB)
Every question here is written for this library rather than taken from a past paper. Write your answer out before opening a mark scheme: the schemes award marks point by point, and the points are much easier to see when you have something of your own to compare against.
Explain why the sequenced genome of a bacterium gives its proteome almost directly, while the sequenced genome of a human does not.
Mark scheme
- B1 bacterial genes are continuous, with no introns, so one gene gives one polypeptide and the coding sequence can be read straight off the DNA
- B1 human genes contain introns, which have to be identified and removed before the coding sequence is known
- B1 alternative splicing lets one human gene give several different polypeptides
- B1 large stretches of the human genome are regulatory rather than coding, and post-translational modification changes the polypeptide again after translation
Compare somatic gene therapy with germ line gene therapy, referring to which cells are altered, what is inherited, and how each stands in law.
Mark scheme
- B1 somatic therapy alters body cells such as bone marrow, retina or airway epithelium, whereas germ line therapy alters a gamete, a zygote or an early embryo
- B1 a somatic change is not inherited, because the cells that become sperm or eggs are untouched, whereas a germ line change is present in every cell of the resulting person, including those cells, and passes to every descendant
- B1 somatic treatment often has to be repeated, because cells that are not stem cells are replaced within weeks, whereas a germ line change is permanent and cannot be withdrawn from the family line
- B1 somatic therapy is licensed for several conditions, whereas clinical use of heritable genome editing is not permitted in the UK and is banned or unauthorised in most countries that regulate it; credit any named jurisdiction stated correctly
Trastuzumab is given only to patients whose breast tumour has been tested first, while patients starting azathioprine may have their TPMT genotype tested first. Explain what each test is for, and explain why the two tests read different genomes.
Mark scheme
- B1 trastuzumab is an antibody with a binding site complementary to the HER2 receptor, so it can only work on a tumour that over-expresses HER2 and the test decides whether the drug is given at all
- B1 TPMT is the enzyme that breaks azathioprine down, so a patient with two low-activity alleles would accumulate the drug and suffer bone marrow damage, and the test decides the dose rather than the drug
- B1 the HER2 test reads the genotype the tumour has acquired through mutation, which the rest of the patient's cells do not carry
- B1 the TPMT test reads alleles the patient inherited, which are present in every cell and will not change
A health minister proposes sequencing the genome of every newborn so that all later prescribing can be personalised. Evaluate this proposal.
Mark scheme
- B1 in favour, a drug that will not work for a patient can be avoided rather than trialled, and doses can be set to prevent adverse reactions such as the bone marrow damage caused by a standard thiopurine dose in a TPMT-deficient patient
- B1 against, the sequencing and the interpretation cost money and staff time that the health service must fund before any saving appears
- B1 against, the reference databases used to judge what a variant means are drawn mostly from people of European ancestry, so the benefit would be smaller for the patients already served worst
- B1 a supported judgement, for example that it is worth doing for the small set of single-gene drug-handling variants with clear evidence, but not as a prediction of common disease, which is polygenic and strongly environmental
Compare genetic screening with genetic counselling, referring to what each one does and to the meaning of non-directive.
Mark scheme
- B1 genetic screening is the laboratory test itself, carried out on an individual to look for particular alleles, whereas genetic counselling is the conversation around the test, explaining what it can and cannot show
- B1 counselling works out the risk to the person and to any children, and sets out the options available, which screening alone does not do
- B1 counselling is meant to be non-directive, meaning the counsellor does not recommend a course of action, because the decision belongs to the person or family being counselled
- B1 screening can happen without counselling, as in newborn heel-prick testing, but a positive predictive result for an adult-onset condition is normally accompanied by counselling before and after the test
A woman is found to carry a pathogenic BRCA1 variant; a separate patient is found to carry the allele for Huntington's disease. Compare what each result means for the person who receives it, referring to penetrance.
Mark scheme
- B1 the BRCA1 result raises the woman's lifetime risk of breast cancer from roughly twelve to fifteen per cent in the general population to about sixty to seventy per cent, which is a large increase but not a diagnosis, since some carriers never develop cancer
- B1 the Huntington's disease result is different because penetrance of the allele is essentially complete, so the result says the disease will develop at some point, though not when
- B1 the BRCA1 result changes what the woman might reasonably choose to do, such as more frequent screening or risk-reducing surgery, whereas nothing currently changes the course of Huntington's disease
- B1 both results are examples of predictive genetic testing, but the certainty of the outcome each one predicts is completely different, which is why many people at risk of Huntington's disease choose not to be tested
Describe how a DNA profile is obtained from a sample such as blood or saliva, using the terms variable number tandem repeat and PCR.
Mark scheme
- B1 DNA is extracted from the sample and a set of loci is chosen, each a variable number tandem repeat that differs in length between people
- B1 each locus is amplified by PCR, using primers that bind to the constant sequences flanking the repeat, so the length of the product depends only on how many repeats that person has
- B1 the amplified products are separated by gel electrophoresis according to their length
- B1 the pattern of fragment lengths obtained, one from each parent at every locus examined, is the profile, and the UK standard test examines sixteen such loci plus a marker that indicates sex
At one locus a mother has alleles of 9 and 14 repeats, and her child has alleles of 9 and 11 repeats. Man A has alleles of 11 and 16; man B has alleles of 7 and 14. Identify which man could be the father, identify which man is excluded, and identify what a single matching locus like this does and does not show.
Person Alleles at this locus (repeats) Mother 9, 14 Child 9, 11 Man A 11, 16 Man B 7, 14 Mark scheme
- B1 the child's allele of 9 repeats could have come from the mother, since she carries a 9
- B1 the child's other allele, 11 repeats, is not carried by the mother, so it must have come from the biological father, who must therefore carry an 11
- B1 man B, with alleles 7 and 14, carries no 11 at this locus and is excluded here, which is strong evidence against paternity (confirmed at further loci, since repeat numbers occasionally mutate), whereas man A, with alleles 11 and 16, could be the father, since he is not excluded
- B1 a single matching locus only shows that man A is not excluded, since an 11-repeat allele may be carried by a substantial fraction of the population; it does not by itself demonstrate paternity, which needs the same result repeated across fifteen or more loci
Explain how a fully sequenced and annotated bacterial genome can be used to identify a candidate antigen for a new vaccine without culturing the pathogen itself, and explain why the same approach is much harder for a eukaryotic parasite.
Mark scheme
- B1 annotation of a bacterial genome is relatively direct because bacterial genes are continuous with no introns, so the sequence can be translated straight into a predicted list of the proteins the bacterium can make
- B1 a surface protein that every strain carries and that the human host does not make is a candidate vaccine antigen among those predicted proteins, since it is one the immune system would meet first
- B1 screening the predicted protein list on a computer is faster and safer than growing the pathogen to find its surface proteins directly, which matters most for organisms dangerous to culture
- B1 the same route is much harder in a eukaryotic parasite because introns must be identified and removed, alternative splicing can give one gene several polypeptides, and much of the genome is regulatory rather than coding
Explain how a labelled DNA probe is used to find out whether a person carries a particular allele.
Mark scheme
- B1 the probe is a short single strand of DNA whose base sequence is complementary to the sequence being looked for, carrying a radioactive or a fluorescent label
- B1 the sample DNA is made single-stranded by heating and the probe is added, and hybridisation occurs wherever the probe meets a complementary sequence, held by hydrogen bonds between complementary bases
- B1 unbound probe is washed away, and the label is then detected, on photographic film or under ultraviolet light, only where the probe has bound
A profile from a crime scene matches a suspect, and the court is told that the probability of such a match in an unrelated person chosen at random is one in a billion. A lawyer says there is therefore a one in a billion chance that the suspect is innocent. Explain why that statement is wrong.
Mark scheme
- B1 the quoted figure is the probability of obtaining a matching profile given that the person is not the source of the sample
- B1 the lawyer has reversed it into the probability that the person is not the source given that the profile matches, which is a different quantity and is not what the figure measures; reversing the two is the prosecutor's fallacy
- B1 the chance that the suspect is not the source depends on how many other people could have left the sample and on the rest of the evidence, which the match probability does not include; accept that the figure assumes an unrelated person, and relatives share far more alleles
Explain the difference between what a DNA microarray shows when labelled DNA from a sample is washed over it, and what it shows when labelled cDNA made from a tissue's mRNA is washed over it.
Mark scheme
- B1 washing labelled DNA from a sample over a microarray identifies which alleles at each probed position that person carries, which is a measurement of genotype
- B1 washing labelled cDNA made from a tissue's mRNA over a microarray identifies which of those genes the tissue is transcribing at the time the sample was taken, which is a measurement of expression rather than genotype
- B1 the microarray itself works the same way in both cases, by hybridisation to a complementary sequence, so the difference lies entirely in what is used as the starting material
Explain why genotyping every patient's CYP2C9 and VKORC1 variants before starting warfarin has not been shown to give a clear benefit over the existing practice of adjusting the dose by monitoring, even though the mechanism linking genotype to dose is well established.
Mark scheme
- B1 common variants of CYP2C9 and VKORC1 do shift the dose of warfarin a patient needs by several times, which is a genuine and well-established mechanism
- B1 existing practice starts every patient on a low dose and adjusts it using blood clotting tests, and this monitoring identifies the correct dose for a given patient within a week or two in any case
- B1 because monitoring reaches the same dose about as quickly as genotyping would predict it, trials comparing the two approaches have not shown a clear improvement in outcome from genotyping first
Describe the two kinds of vector used to deliver a gene into a patient's cells in somatic gene therapy, and describe one limitation of using a viral vector.
Mark scheme
- B1 a modified virus, stripped of the genes that would let it cause disease and carrying the therapeutic gene instead, can be used to carry the gene into cells
- B1 alternatively a liposome, a small sphere of phospholipid that fuses with the cell-surface membrane, can be used to deliver the gene without any virus at all
- B1 a limitation of a viral vector is that the patient's immune system may attack it, or that a vector integrating at a random position in the genome may land inside another gene, such as a proto-oncogene, causing serious harm
State what a genome project produces, and state what annotation adds to that product afterwards.
Mark scheme
- B1 a sequence of bases for the organism, coding and non-coding alike
- B1 annotation locates the genes within that sequence and works out which non-coding regions do something, and it is a separate and slower job done afterwards
Practise genome analysis, genetic screening and gene therapy one question at a time
The player marks nothing for you. It shows one question, waits, then shows the scheme so you can mark yourself, and brings a question back sooner when it went badly.